Pharmafile Logo

News and Press Releases

Asgard Therapeutics announces oral presentation at ASGCT 2026, showcasing advanced preclinical data on AT-108 – its first-in-class, off-the-shelf, gene-based cancer immunotherapy

AT-108 induces powerful, personalized anti-cancer responses by forcing tumor cells to present their antigens to the immune system Data to be presented at ASGCT 2026 show when used as a...

Category: Biotechnology, Other, Pharmaceutical
Posted: April 27, 2026

Asgard Therapeutics
info@asgardthx.com
Medicon Village, 223 81 Lund, Sweden

Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026 

Asgard’s immunotherapy, AT-108, induces systemic, dose-dependent efficacy with broad tumor activity in preclinical studies and key biomarkers identified AT-108 combines the advantages of an off-the-shelf gene therapy whilst offering a...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 17, 2026

Asgard Therapeutics
info@asgardthx.com
Medicon Village, 223 81 Lund, Sweden

Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure

FB301 was safe and well tolerated in healthy female subjects, with all primary and secondary endpoints met Clinically meaningful microbiome modulation observed, including significant improvement up to 6-month follow-up Results...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 16, 2026

Freya Biosciences
info@freyabiosciences.com
Fruebjergvej 3, 2100 Copenhagen, Denmark

Recipharm supports landmark trial of next generation pneumococcal vaccine developed by ImmBio and iiCON

Recipharm delivers cGMP manufacture of PnuBioVax® enabling progression to phase 2 clinical trials in Malawi Demonstrates Recipharm’s agility and flexibility, completing full tech transfer, scale-up and process optimisation within three...

Category: BioManufacturing, Drug Delivery, Manufacturing and Packing, Other, Pharmaceutical
Posted: October 15, 2025

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: April 18, 2025

Regeneron
ukinfo@regeneron.com
The Charter Building, Vine Street, Uxbridge, Middlesex, United Kingdom, UB8 1JG

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline

Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front....

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025

Sanofi
One Onslow Street, Guildford, Surrey, GU1 4YS, UK

Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy candidate AT-108 to clinical trial stage

11 June 2024 -- Lund, Sweden -- Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announced it selected Exothera, a leading...

Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 11, 2024

Asgard Therapeutics
info@asgardthx.com
Medicon Village, 223 81 Lund, Sweden

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseases Felzartamab is an investigational anti-CD38 monoclonal antibody that, through its...

Category: Drug Discovery, Pharmaceutical
Posted: May 22, 2024

Biogen
Biogen International GmbH Neuhofstrasse 30 6340 Baar Switzerland

Gyros Protein Technologies introduces Gyrolab Generic Rodent ADA Kit Reagents to support preclinical immunogenicity assessment

Ready-to-use kit expands range of bioanalysis kits, and enables generic detection of immune complexes in rodent samples 2 May 2024 -- Uppsala, Sweden -- Gyros Protein Technologies, a pioneer in...

Category: BioManufacturing, Drug Discovery
Posted: May 2, 2024

Gyros Protein Technologies
information@gyros.com
Gyros AB, Uppsala Science Park, SE-751, 83 Uppsala, Sweden

argenx Announces MHRA Licensing of Subcutaneous VYVGART (efgartigimod alfa) for generalised Myasthenia Gravis

VYVGART is now licensed for both intravenous (IV) and self-administered subcutaneous (SC) use in the UK 7 February 2024 -- Gerrards Cross, UK -- argenx UK, part of argenx, a...

Category: Biotechnology
Posted: February 7, 2024

argenx
ukmediainfo@argenx.com
Spaces Gerrards Cross Chalfont Park, Building 1 Gerrards Cross, SL9 0BG